English  |  正體中文  |  简体中文  |  Items with full text/Total items : 17482/19768 (88%)
Visitors : 6280648      Online Users : 535
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: http://ir.cnu.edu.tw/handle/310902800/31665


    標題: A histone deacetylase inhibitor enhances expression of genes inhibiting Wnt pathway and augments activity of DNA demethylation reagent against nonsmall-cell lung cancer
    作者: Shieh, Jiunn-Min
    Tang, Yen-An
    Hu, Fu-Han
    Huang, Wei-Jan
    Wang, Ying-Jan
    Jen, Jayu
    Liao, Sheng-You
    Lu, Ying-Hung
    Yeh, Ya-Ling
    Wang, Tseng-Wei
    Lin, Pinpin
    Wang, Yi-Ching
    貢獻者: Chi Mei Med Ctr, Div Chest Med, Dept Internal Med
    Chia Nan Univ Pharm & Sci, Ctr Gen Educ
    Natl Cheng Kung Univ, Inst Basic Med Sci
    Natl Cheng Kung Univ, Dept Pharmacol
    Taipei Med Univ, Grad Inst Pharmacognosy
    Natl Cheng Kung Univ, Dept Environm & Occupat Hlth
    Natl Hlth Res Inst, Natl Inst Environm Hlth Sci
    關鍵字: histone deacetylase inhibitor
    5-aza-2-deoxycytidine
    Wnt signal
    lung cancer
    日期: 2017-05-15
    上傳時間: 2018-11-30 15:52:06 (UTC+8)
    出版者: Wiley
    摘要: Development of new inhibitors targeting histone deacetylases (HDACs) with improved efficacy for solid tumor therapy is urgently needed. Here, we report the development of a novel HDAC inhibitor TMU-35435 and verify it as a single agent and in combination treatment with DNA demethylation reagent 5-aza-2-deoxycytidine (5-aza-dC) in lung cancer preclinical models. TMU-35435 exerted cancer-specific cytotoxicity via mitochondria-mediated apoptosis. Expression microarrays revealed a unique TMU-35435-induced gene networks enriched in biological processes, including negative regulation of cell proliferation and Wnt receptor signaling pathway compared to FDA-approved HDAC inhibitor SAHA. TMU-35435 inhibited tumor growth with good pharmacokinetic properties and safety features in lung orthotopic and subcutaneously implanted xenograft models. TMU-35435 and 5-aza-dC showed synergistic antitumor effects through reactivation of tumor suppressor genes and those genes encoding negative regulators of Wnt signaling pathway in vitro and in vivo. Some genes showed additive inhibition of DNA methylation upon TMU-35435 and 5-aza-dC combined treatment. Our findings suggested that TMU-35435 is a potential HDAC inhibitor for lung cancer treatment as a single agent and in combination with 5-aza-dC. What's new? Histone deacetylases (HDACs) fill a critical role in the epigenetic regulation of gene expression. In cancer, however, their over activity contributes to aberrant gene expression and tumor growth. HDAC inhibition is therefore an appealing therapeutic avenue. Here, a novel HDAC inhibitor, TMU-35435, when administered as a single agent in preclinical lung cancer models, effectively inhibited tumor growth. Given together with a DNA demethylation reagent, TMU-35435 acted synergistically to induce cell death via reduced DNA methylation and reactivation of tumor suppressor genes that encode negative Wnt signaling regulators. Safety profiles in mice further highlight the potential of TMU-35435 as a cancer therapy.
    關聯: International Journal of Cancer, v.140, n.10, pp.2375-2386
    Appears in Collections:[通識教育中心] 期刊論文

    Files in This Item:

    File Description SizeFormat
    ijc.30664.pdf1453KbAdobe PDF0View/Open
    index.html0KbHTML235View/Open


    All items in CNU IR are protected by copyright, with all rights reserved.


    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback